This stock is making smart investments in biotech -- and not just through partnerships, but through actual equity investments in biotechs like Regeneron (NASDAQ:REGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY). It's a smart play for income investors (3.5% dividend yield) and growth investors alike.

Of course, there are threats and headwinds -- what company doesn't have them? -- but in the video below, Motley Fool health care analysts Michael Douglass and David Williamson reveal why Sanofi (NYSE:SNY) is their favorite European pharma stock.

Leaked: This coming blockbuster could make even Sanofi jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.